Given the recognized over-activation of JAK-STAT signaling in advanced ABC-type DLBCL, the mechanism of anti-tumor effect of STAT targeting therapy should be further investigated in future studies. This evidence concerns the gene SOAT1 and diffuse large B-cell lymphoma.